XML 67 R55.htm IDEA: XBRL DOCUMENT v3.7.0.1
COMMERCIAL PARTNERS AND OTHER AGREEMENTS DepoCyte Product Discontinuance (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
DepoCyte Discontinuation [Line Items]          
Revenues $ 70,934 $ 69,640 $ 140,217 $ 135,114  
Severance Costs     365    
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation 5,000        
Discontinued Operation, Amounts of Material Contingent Liabilities Remaining 2,605   2,605    
Discontinued Operations - Remaining Lease Costs     1,865    
Discontinued Operations - Fixed Asset and Inventory Writedown     2,397    
Asset Retirement Obligation 375   375    
Asset Retirement Obligation, Liabilities Incurred     375    
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax (4,495) $ 0 (4,495) $ 0  
Discontinued Operations Assets removed from Service     (2,397)    
Total Change in Discontinued Operations Balance     (2,397)    
Supplemental Unemployment Benefits, Severance Benefits 365   365    
Discontinued Operations - Residual Lease Costs 1,865   1,865    
DepoCyte [Member]          
DepoCyte Discontinuation [Line Items]          
Revenues         $ 276,400
Percentage of total revenue         2.60%
Inventory Write-down 500        
Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax $ (4,495)   $ 5,002